Chevy Chase Trust Holdings Inc. lessened its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 4.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 254,083 shares of the medical instruments supplier’s stock after selling 11,228 shares during the quarter. Chevy Chase Trust Holdings Inc. owned about 0.10% of Becton Dickinson and worth $54,389,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of BDX. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in shares of Becton Dickinson and by 55.8% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 240 shares in the last quarter. Harfst & Associates Inc. lifted its position in Becton Dickinson and by 46.4% in the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after buying an additional 221 shares during the last quarter. Harvest Fund Management Co. Ltd lifted its position in Becton Dickinson and by 82.8% in the 2nd quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock worth $146,000 after buying an additional 338 shares during the last quarter. Acrospire Investment Management LLC lifted its position in Becton Dickinson and by 259.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock worth $162,000 after buying an additional 600 shares during the last quarter. Finally, Valeo Financial Advisors LLC bought a new stake in Becton Dickinson and in the 3rd quarter worth approximately $191,000. 75.56% of the stock is owned by institutional investors and hedge funds.
Shares of Becton Dickinson and Co (NYSE:BDX) traded up $4.55 during mid-day trading on Wednesday, reaching $219.95. The company’s stock had a trading volume of 1,322,920 shares, compared to its average volume of 1,700,000. The company has a quick ratio of 0.93, a current ratio of 1.54 and a debt-to-equity ratio of 1.04. Becton Dickinson and Co has a 12-month low of $175.66 and a 12-month high of $248.39. The company has a market capitalization of $50,460.00, a P/E ratio of 167.90, a P/E/G ratio of 1.50 and a beta of 1.12.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.07. The firm had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The business’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.33 earnings per share. equities analysts forecast that Becton Dickinson and Co will post 10.94 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be issued a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.36%. Becton Dickinson and’s dividend payout ratio is presently 229.01%.
A number of research firms recently weighed in on BDX. Morgan Stanley boosted their target price on Becton Dickinson and from $245.00 to $250.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 7th. Piper Jaffray Companies restated an “overweight” rating and issued a $260.00 target price (up previously from $223.00) on shares of Becton Dickinson and in a research report on Tuesday, February 6th. Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 target price for the company in a research report on Friday, January 19th. Bank of America restated a “buy” rating and issued a $260.00 target price on shares of Becton Dickinson and in a research report on Friday, January 19th. Finally, Citigroup upgraded Becton Dickinson and from a “sell” rating to a “neutral” rating in a research report on Friday, January 5th. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. Becton Dickinson and currently has an average rating of “Buy” and a consensus target price of $237.27.
In related news, Director Timothy M. Ring sold 269,661 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the completion of the transaction, the director now owns 295,753 shares in the company, valued at $64,420,918.46. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.00% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/14/chevy-chase-trust-holdings-inc-has-54-39-million-position-in-becton-dickinson-and-co-bdx-2.html.
Becton Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.